Nonalcoholic fatty liver disease in adolescents receiving valproic acid

Epilepsy and Behavior

Volumn 20, Issue 2, 2011, Pages 382-385

  Verrotti, Alberto ^a   Agostinelli, Sergio ^a   Parisi, Pasquale ^b   Chiarelli, Francesco ^a   Coppola, Giangennaro ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Valproic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VALPROIC ACID;

ABDOMINAL OBESITY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARM CIRCUMFERENCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; EPILEPSY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; ALANINE TRANSAMINASE; ANTICONVULSANTS; BLOOD PRESSURE; BODY WEIGHT; CHILD; CHOLESTEROL; CROSS-OVER STUDIES; DRUG-INDUCED LIVER INJURY; EPILEPSY; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 79951673165     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.12.012     Document Type: Article

References (22)

1. Verrotti A., la Torre R., Trotta D., Mohn A., Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm Res 2009, 71:125-131.
2. Verrotti A., Manco R., Agostinelli S., Coppola G., Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010, 51:268-273.
3. Schwimmer J.B., Deutsch R., Rauch J.B., Behling C., Newbury R., Lavine J.E. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003, 143:500-505.
4. Tominaga K., Fujimoto E., Suzuki K., Hayashi M., Ichikawa M., Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009, 14:142-149.
5. Schwimmer J.B., Deutsch R., Kahen T., Lavine J.E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
6. Luef G.J., Waldmann M., Sturm W., et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004, 55:729-732.
7. Luef G., Rauchenzauner M., Waldmann M., et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009, 86:42-47.
8. Cacciari E., Milani S., Balsamo A., et al. Italian cross-sectional growth charts for height, weight and BMI (6-20y). Eur J Clin Nutr 2002, 56:171-180.
9. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989, 30:389-399.
10. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. Epilepsia 2001, 42:796-803. for the International League Against Epilepsy (ILAE).
11. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004, 114(2, Suppl. 4th Report):555-576. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.
12. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
13. Knight J.R., Shrier L.A., Bravender T.D., Farrell M., Vander Bilt J., Shaffer H.J. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med 1999, 153:591-596.
14. Cook S., Weitzman M., Auinger P., Nguyen M., Dietz W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157:821-827.
15. Park H.S., Han J.H., Choi K.M., Kim S.M. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005, 82:1046-1051.
16. Alavian S.M., Mohammad-Alizadeh A.H., Esna-Ashari F., Ardalan G., Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int 2009, 29:159-163.
17. Schwimmer J.B., McGreal N., Deutsch R., Finegold M.J., Lavine J.E. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005, 115:e561-e565.
18. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992, 89:495-501.
19. Keskin M., Kurtoglu S., Kendirci M., Atabek M.E., Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005, 115:e500-e503.
20. Jeavons P.M. Non-dose-related side effects of valproate. Epilepsia 1984, 25(Suppl. 1):S50-S55.
21. Dreifuss F.E., Santilli N., Langer D.H., Sweeney K.P., Moline K.A., Menander K.B. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987, 37:379-385.
22. Fishbein M.H., Mogren C., Gleason T., Stevens W.R. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2006, 42:83-88.